Related Experiment Video
Updated: Feb 24, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms
T D Filippatos1, V Tsimihodimos1, G Liamis1
1Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Aims:
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that affect serum electrolytes levels. The aim of this review is the detailed presentation of the associated mechanisms of the SGLT2 inhibitors-induced electrolyte abnormalities.
Materials And Methods:
Eligible trials and relevant articles published in PubMed (last search in July 2017) are included in the review.
Results:
SGLT2 inhibitors induce small increases in serum concentrations of magnesium, potassium and phosphate. The small increase in serum phosphate concentration may result in reduced bone density and increased risk of bone fractures, mainly seen with canagliflozin, but recent meta-analyses did not show increased risk of bone fractures with SGLT2 inhibitors.
Conclusion:
The increases in serum electrolytes levels may play a role in the cardiovascular protection that has been recently reported with empagliflozin and canagliflozin.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Secondary Active Transport
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Glucose Absorption Into the Small Intestine

